Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the last decade. The major drivers for choosing ion channel targets and specific therapeutic indications will be assessed, and examples provided of different ligand modalities applied to ion channels (small molecules, biologicals such as toxins and antibodies, and protein modulation pathways).
This webinar features Marc Rogers, Director at Albion Drug Discovery Services, and Jean-Francois Rolland, Director of Biological Sciences at Axxam.
Case studies will be provided to illustrate both successful projects and recent challenges for programs targeting voltage- and ligand-gated ion channels in the periphery and CNS for a variety of both common and rare cardiac, musculo-skeletal, respiratory, renal, ophthalmological, pain, epilepsy and neuropsychiatric diseases.
You will learn:
- Why ion channels are important and tractable drug discovery targets
- Recent, current, and future ion channel targets and their therapeutic indications, including the latest high impact work on organellar ion channels
- Strengths and weaknesses of different drug discovery modalities targeting ion channels (small molecules, biologicals, protein modulation pathways)
A Q&A session follows the webinar presentations.
Watch the webinar on-demand now!
